Sutro Biopharma, Inc.
STROSutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies and other biologics. It employs its proprietary Cell-Free Protein Synthesis platform to develop biologics with precise modification and enhanced efficiency. The company's pipeline includes bispecific antibodies, antibody-drug conjugates, and novel protein therapeutics aimed at treating various cancers and other diseases.
Company News
Sutro Biopharma announced promising preclinical data for its ADC pipeline at AACR 2026, with STRO-004 demonstrating robust antitumor activity across multiple solid tumor models and improved efficacy versus benchmark ADCs. The company also presented data for STRO-006 and STRO-227, with IND submissions planned for 2026. Partner Astellas presented r...
Sutro Biopharma announced the pricing of an underwritten offering of 7,868,383 shares at $13.98 per share, generating approximately $110 million in gross proceeds. The offering includes participation from multiple investors and is expected to close on February 11, 2026. Proceeds will be used for research, clinical development, manufacturing, and ...
Sutro Biopharma initiated a Phase 1 clinical trial for STRO-004, a next-generation antibody-drug conjugate targeting tissue factor in various solid tumors. The trial aims to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity across multiple cancer types.
Sutro Biopharma announced the initiation of its Phase 1 study for STRO-004, a Tissue Factor ADC, and selected PTK7 as the target for its first dual-payload candidate STRO-227, showcasing its innovative antibody-drug conjugate platform.
Sutro Biopharma will present preclinical data on advanced antibody-drug conjugates (ADCs) at the 16th Annual World ADC Conference, highlighting innovations in dual-payload ADCs and cell-free manufacturing platforms to potentially improve cancer treatment.
